Small and mid-size CROs occupy about 44% of the market share of outsourced development works, approximately. These CROs are gaining interest and becoming the choice for startups, small and mid-sized pharmaceutical and biological companies. While, in the first part of this article series on “Contract Research Organizations For Your Clinical Trials“, the top 10 CROs were discussed, it’s rather important to understand perspective about small to mid-size CROs as well.
The number, capabilities, and approach of these small to mid-size CROs are increasing consistently and it won’t be wrong to say that they now play a crucial role in drug development worldwide, particularly with the advantages they bring.
Advantages with a small to mid-size CROs
- Single point of contact and flexibility,
- Easy to collaborate in a sponsor’s program from a strategic and cultural perspective,
- More accessible and affordable to small to mid-size pharmaceutical companies in order to accommodate limited funds
Choosing a small to mid-size range CROs is complex compared to large CROs as it presents more challenges in selecting the right CRO and the number in the list is extensive.
To simplify and make an efficient choice, this list can be classified on the basis of
- the geographic region of their presence,
- the phase of trials they focus upon, and
- therapeutic area of expertise.
Small and mid-range CROs selection based on region
On the basis of geographic presence, small and mid-range CROs can be considered in the following regions
- North America
- Asia Pacific
- The Middle East and Africa
- Latin America
North America region is expected to dominate the contract research organizations (CRO) market with the potential in research that they bring. This may be due to the presence of a large number of biopharmaceutical, and pharmaceutical companies in this region, increasing R&D expenditures and focus on outsourcing for clinical research studies. The North America contract research organization (CRO) market is expected to reach US$ 30,730.1 Mn in 2025.
U.S. firms have more than half of the world’s research & development in pharmaceuticals spending USD 75 billion according to the Pharmaceutical Research and Manufacturers Association (PhRMA) and are a potential hub for small and mid-range CROs.
Example: Catawba Research, LLC is a full-service contract research organization (CRO) that provides clinical management services to pharmaceutical, device, formulation development, and biotechnology companies. Their strong therapeutic areas include dermatology, women’s health, ophthalmology, and gastroenterology.
Europe was the second-largest dominating market globally for contract research organizations in the year 2018. The Europe CRO market is expected to reach US$ 22,157.62 Mn in 2025 from US$ 12,476.8 Mn in 2017. The growth of the CRO market is driven by many factors such as a rise in the number of clinical trials, increase expenditure on research and development in the country. R&D spending by the biopharmaceutical companies has been increased over the years according to a report published by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Along with the growth of big CRO, there is also a growing demand for small and mid-range CROs in this region.
Example of a European CRO: Pivotal is a full-service CRO offering service and expertise in oncology, internal medicine, non-interventional studies, medical monitoring, pharmacovigilance, and auditing.
The clinical trial industry in the Asia Pacific region is growing in multiples over the past few years. The revenue is expected to increase at a 20% compound annual growth rate (CAGR), from 2016 to 2021 compared with the rest of the world’s 11.4% CAGR (see ref. 6). This growth is evident particularly in countries like Australia and India, which also have a major share of the business.
- This turnaround is expected to be due to large patient naive, faster completion rates, and cost-saving,
- Compared to the high per-patient cost in the United States, the Asia-pacific countries are considerably low-cost regions. Even Australia, which is often considered a western country, offers considerable cost-advantage compared to the USA.
- On the other hand, however, there are regulatory concerns surrounding the developing nations.
- Despite this challenge, the APAC is expected to emerge as the fastest-growing regional market due to the rapidly increasing prevalence of therapeutic and chronic diseases like diabetes, infectious diseases, and cardiovascular diseases.
Examples of an Asia-Pacific CRO: CROs that have a pan Asia-Pac coverage are limited. Most of the CROs specialize in their respective regions of presence, eg Nucleon in India. It is better to make the most of these local CROs to get maximum advantage of Asia-Pac.
Credevo can help in recommending CROs for your projects in Asia-Pac.
The Middle East and Africa
The size of the middle east African clinical trial market was valued at USD $1.36 and projected to reach USD $1.96 by 2024 at a CAGR of 7.55% during the period of 2019-2024. This a great opportunity for regional CROs which are small and mid-sized CROs. Emerging potential, advanced technology and upgrading of the workforce to a highly skilled and qualified one make these countries the choice for many pharmaceutical companies.
Example: ACRO (African Clinical Research Organisation) is a South African, full-service contract research organization that offers services in regulatory affairs, clinical management, and monitoring services, data management, and medical affairs.
Latin America is often considered as a preferable region during the early phases of drug development because of the following advantages such as
- Enhanced patient recruitment rate due to growing population, and require fewer sites
- Strong enrollment rates and the high retention percentage
- Availability of qualified and committed medical professionals
- Trained and experienced staff in ICH GCP regulated research
- The established regulatory environment in most of the countries
- a significant portion of the population is under 14 years old which is about 27% (an advantage for pediatric trials and rare disease trials)
Example: Activa-CRO is a Latin American full-service contract research organization (CRO), based in Buenos Aires, Argentina.
Small and mid-range CROs selection based on the phase of the study
The choice of CRO selection also varies with the phase of the trial you need to conduct. For example Phase I clinical trials are an integral step in the drug development process. Specific factors may influence the timelines and success of these studies, such as
- Modern and efficient facilities to conduct phase I studies
- Clinical, therapeutic, medical, and regulatory experience
- Efficient processes and access to study participants
- Services from protocol design to final study reporting
Efficient study design for first in humans, proof of concept (PoC), drug interaction (DI), single ascending dose/multiple ascending doses (SAD/MAD), and cardiac safety studies are essential for ensuring safe and efficient study conduct.
CRO specialized in Phase I and Phase II studies
Example: Alta science is a mid-size early phase contract research organization, in Canada and the U.S., offering biopharmaceutical companies a flexible approach to early drug development, including preclinical safety testing, clinical pharmacology (Phase I to Phase II).
CRO specialized in Phase III & Phase IV studies
Almost all CROs are ready to undertake phase III-IV studies, particularly due to the big-ticket size of these trials. However, the selection of CRO for big studies like phase III clinical trials must be done with due consideration.
It’d be prudent to explore multiple choices before zeroing on the final choice. These choices may also be dependent on past experience, local advantage, or access to patients, particularly in oncology and rare disease trials.
Example: Sofpromed provides full clinical trial management services for phase III studies.
Small and mid-size CRO selection based on therapeutic area
Deep therapeutic knowledge and understanding of the key issues combined with clinical development experience are crucial factors in many areas of clinical trials, starting from the development of protocols to meeting specific needs of the project. It’s but obvious that we choose a CRO that is expert in the particular therapeutic area of interest for a successful trial.
CRO specialized in rare disease clinical trials
Rare disease clinical trials require innovative thinking and savvy adjustments along the way. There is often no standard trial design or formula for rare disease study success. Rare and orphan disease trials may be rife with challenges, but they are also the most rewarding projects.
Example of a rare disease CROs: ARG -Atlantic Research Group provides its expertise in rare disease clinical trials.
CRO specialized in cancer clinical trials
Oncology trials require specific trial design expertise, often include biomarker and companion diagnostics, and attrition rates tend to be high. A clinical research organization with broad cancer research clinical trial experience and deep knowledge of regulatory requirements can mitigate risks associated with these complex studies.
Examples of oncology-focused CRO: IDDI is an oncology CRO led by a highly-skilled biostatistical and clinical team of thought-leaders in oncology research.
CRO specialized in GI clinical trials
This is one of those therapeutic segments, where many CROs come across as capable of conducting clinical trials. However, if your clinical trial has unusual or demanding specifications, it may be better to go with someone, who has worked a lot on gastrointestinal clinical trials.
Example: Robarts Clinical Trials (Now, Alimentiv) is one such example of a niche GI Contract Research Organization. They are experts in GI clinical trial design, ranging from proof of concept trials to large scale phase 4 studies.
CROs specialized in Cardiology clinical trials
Example: Cardialysis is one of the leading cardiovascular research organization with an exclusive focus on cardiology, providing the full range of clinical research and cardiovascular core laboratory services.
How to choose the best CRO for your clinical trial?
Finding the right CRO partner is as crucial in the success of clinical trials, as probably the site or investigator. That’s why it is important to perform this selection on the basis of carefully selected criteria and parameters.
Credevo has extensive experience and expertise in performing such selection for our clients. Credevo often works as an extended arm of pharma / biotech companies in building clinical development strategy and selecting the right kind of vendors (including CROs) for successful and accelerated completion of clinical trials.
Discuss your clinical development needs for free with us today. We can help you in developing a successful strategy and selection of the most suitable CRO for your clinical trial.